4th Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis

Register Now

October 12, 2022  10:30 AM – 12:00 PM ET

Overview

Management of myeloproliferative neoplasms (MPNs) is undergoing rapid evolution as novel treatment principles and therapeutic agents are introduced into clinical practice. In particular, new therapies addressing key challenges for patients with MPNs offer potential benefit, but their use must be considered carefully alongside clinical and patient characteristics.

This live Virtual Tumor Board^® webcast is specifically designed to meet the needs of busy clinicians who treat patients with MPNs by providing the framework through which these cancers should be diagnosed and managed. Following a presentation on recent advances in polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), the faculty will discuss a series of cases constructed to highlight key challenges faced by patients with MPNs.

Benefits of Attending

• Challenge the experts with your burning clinical questions
• Learn how you can use the expanding tool kit of therapies available for MPN treatment
• Engage thought leaders in MPN management on emerging treatment options

Target Audience

This educational activity is directed toward medical oncologists, heme/oncs, NP/PAs, and nurses

Learning Objectives

Upon completion of this activity, participants will be able to:

• Explain factors that inform individualized treatment of patients with myeloproliferative neoplasms (MPNs) and the potential impact of these factors on risk stratification and treatment decision-making
• Discuss efficacy and safety profiles of current and emerging treatment strategies across the MPN spectrum including patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET)
• Identify patients with MPN who may benefit from participation in clinical trials based on individual and disease characteristics
• Apply multidisciplinary strategies to identify and manage treatment-related toxicities and disease-related symptoms.

4th Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis Wednesday, October 12, 2022 10:30 AM – 12:00 PM ET

10:00 AM	Welcome, Program Overview, and Pre-Assessment Questions
10:05 AM	Brief Overview on Diagnosis and Treatment Methodologies Across the MPN Spectrum in 2022	John Mascarenhas
10:35 AM	Case #1: Patient with intermediate-risk MF, previously treated with an approved JAK2 inhibitor presents with severe cytopenia	Naveen Pemmaraju
10:45 AM	Case #2: Patient with high-risk MF who is not a candidate for HSCT	Naveen Pemmaraju
10:55 AM	Case #3: Patient with high-risk PV is treatment naïve	Heinz Gisslinger
11:05 AM	Case #4: Patient with high-risk PV is treatment-experienced	Kathryn Johnson
11:15 AM	Question-and-answer session
11:25 AM	Post-assessment questions
11:30 AM	Meeting Adjourns

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. 

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.